The Microdosing Secret Reshaping Weight Loss, Muscle & the Brain’s Reward System | Jay Campbell

Jay Campbell has spent more than two decades bringing hormone and peptide optimization into the mainstream, and this conversation applies that experience to the most talked-about drug class in medicine.

Jay traces his path from a 1999 basketball injury that exposed his low testosterone, to underground forums, to the book that became a bestseller, to his tenth book, Living Leaner, Longer, Stronger. He and Dr. Crawford then dig into why standard GLP-1 dosing, built around the package insert, may do more harm than good, and why Jay believes a “start low, go slow” approach protects muscle, metabolism, and mood.

The second half moves to the brain and to what could come next. Dr. Crawford walks through where GLP-1 receptors sit in the reward pathways, and Jay shares what he and his community report about cravings, Klotho, and a modified myostatin inhibitor from BioLongevity Labs.

Key Takeaways

Here are the main ideas Jay and Dr. Crawford return to throughout the conversation:

• Start Low, Go Slow: Jay argues that titrating GLP-1 doses upward per the package insert pushes people past what they need, and that microdosing delivers results with fewer side effects.
• Protect Your Muscle: Not eating is not an effective strategy. Without resistance training, enough protein, and hormonal support, rapid weight loss can mean muscle loss and a depleted look.
• Testosterone Resistance: Citing Dr. Keith Nichols, Jay describes androgen receptors desensitized by environmental chemicals such as BPA and phthalates. Dr. Crawford points to a hot car as one of the largest daily exposures.
• Reward Pathway Effects: GLP-1 receptors are spread across the brain’s dopamine reward circuitry, which may explain reports of reduced cravings for alcohol, nicotine, and processed food. Jay also warns that overuse can dull desire and motivation.
• Beyond Weight Loss: Both discuss possible future uses in neurological conditions, including autism. Dr. Crawford notes this is a plausible hypothesis he has not tested clinically.
• Klotho and Longevity: Jay describes Klotho as an endocrine protein tied to cellular aging and shares the changes he reports in his own vision and sexual function after nearly a year of use.
• Myostatin Inhibition: Jay explains how a modified follistatin-based inhibitor is designed to build muscle without binding activin, and why he sees it as a companion to GLP-1 use.
• Lessons From Self-Experimentation: After 26 years, Jay credits never abusing doses, plus hard lessons on injection sites, for keeping him out of serious trouble.

Share the Love

Never miss an episode by subscribing via Apple Podcasts, Spotify, Amazon Music, or by RSS!